BOT price action, page-42

I wonder whether the sea cucumber gets the safety 'all clear' which is very important and par for the course that these dudes below are talking about with a novel molecule.

Hopefully BOT's topicals continue with the best safety profile Matt has ever seen. This below for an arthritis phase 3 drug that seems to be hitting its mark.

Gilead and Galapagos have notched another series of late-stage wins for their JAK inhibitor filgotinib, with one analyst saying safety “looks clean” after recent scares in the class.

But safety is still something of an overhang, to quote Jefferies, given the black box warnings and DVT/PE events that have overshadowed the class as a whole.

While analysts see these issues as not being a major concern for the pair, the two are racing to clear up the one safety area in which filgotinib may have a disadvantage: testicular toxicity.

So I hope for their sake that after getting into the third and final phase that this new drug filgotnib doesn't go balls up with this major safety profile issue. Then again you have to think laterally. Firstly only give it to females. Not bad I think but half the population is excluded. Secondly and hows this for evergreening, change the drug name from filgotnib to filgotsnib and give prospective clients a free castration so they have no chance of getting this problem. Drastic sure, but what would you prefer hanging around when you might be old and grey, severe arthritis or a tobacco pouch?

Safety in numbers, safety in clinical trials. Both important.